Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6195842 | 0.79 | LMNA (0.56) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL6192276 | 0.79 | LMNA (0.56) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL8342494 | 0.77 | LMNA (0.75) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL6195822 | 0.73 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL8345917 | 0.73 | LMNA (0.78) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL9365654 | 0.72 | LMNA (0.71) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL7340898 | 0.71 | LMNA (0.76) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL9365834 | 0.69 | LMNA (0.49) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL9369302 | 0.68 | LMNA (0.78) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL16736488 | 0.68 | P2RX4 (0.43) | LMNAALDH1A1MEN1KMT2AP2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150148292-A1 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO | UNIV EMORY (US) | 2015-05-28 | — | — | US | claimed |
| WO-2014011540-A1 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2014-01-16 | — | — | WO | claimed |
| US-10933169-B2 | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto | EMORY UNIVERSITY (US) | 2021-03-02 | — | — | US | disclosed |
| US-10434220-B2 | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto | EMORY UNIVERSITY (US) | 2019-10-08 | — | — | US | disclosed |
| US-20160089478-A1 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO | UNIV EMORY (US) | 2016-03-31 | — | — | US | disclosed |
| US-20150148292-A1 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO | UNIV EMORY (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148292-A1 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO | UNIV EMORY (US) | 2015-05-28 | — | — | US | disclosed |
| US-8753641-B2 | Combination of intercalating organometallic complexes and tumor seeking biomolecules for DNA cleavage and radiotherapy | UNIVERSITY OF ZURICH (CH) | 2014-06-17 | — | — | US | disclosed |
| WO-2014011540-A1 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014011540-A1 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20090280057-A1 | Combination of Intercalating Organometallic Complexes and Tumor Seeking Biomolecules for DNA Cleavage and Radiotherapy | MALLINCKRODT INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-7582295-B2 | Combination of intercalating organometallic complexes and tumor seeking biomolecules for DNA cleavage and radiotherapy | UNIVERSITY OF ZURICH (CH) | 2009-09-01 | — | — | US | disclosed |
| EP-1154798-B1 | MOLECULES FOR THE TREATMENT AND DIAGNOSIS OF TUMORS | UNIV ZUERICH (CH) | 2006-05-10 | — | — | EP | disclosed |
| US-6844425-B1 | Combination of intercalating organometallic complexes and tumor seeking biomolecules for DNA cleavage and radiotherapy | MALLINCKRODT INC. (US) | 2005-01-18 | — | — | US | disclosed |
| EP-1154798-A1 | MOLECULES FOR THE TREATMENT AND DIAGNOSIS OF TUMORS | Mallinckrodt Inc. (US) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050086-A1 | MOLECULES FOR THE TREATMENT AND DIAGNOSIS OF TUMORS | MALLINCKRODT INC. (US) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280057-A1 | Combination of Intercalating Organometallic Complexes and Tumor Seeking Biomolecules for DNA Cleavage and Radiotherapy | ERCC4, DDB1, XRCC6 | LMNA 627/4885SMN1; SMN2 4810/4885ALDH1A1 2867/4885 |
| US-20150148292-A1 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO | BMP4, BMP2, BMP1 | LMNA 1054/4885SMN1; SMN2 4239/4885ALDH1A1 3881/4885 |
| US-10434220-B2 | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto | BMP2, BMP4, BMP1 | LMNA 2891/4885SMN1; SMN2 3133/4885ALDH1A1 1840/4885 |
| US-10933169-B2 | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto | BMP2, BMP4, BMP1 | LMNA 2891/4885SMN1; SMN2 3133/4885ALDH1A1 1840/4885 |
| US-20160089478-A1 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO | BMP2, BMP4, BMP1 | LMNA 2891/4885SMN1; SMN2 3133/4885ALDH1A1 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.